Registration 333-291359
S-4/A · 2026-04-13 · 0001104659-26-042689
Terms from the governing filing for this registration; not a claim that the offering is open today.
Company research
BEACON TOPCO, INC.
CIK 2094256Updated Sep 25, 2026
Filing activity
Latest filing
10 filings on record · 8-K, SC TO-I/A, SC TO-I, 10-Q, SP 15D2, 424B3.
Recent filings
Entry into a Material Definitive Agreement · Other Events
Items 1.01, 8.01, 9.01
SC TO-I/A - filed by BEACON TOPCO, INC. regarding BEACON TOPCO, INC.
Material Modification to Rights of Security Holders · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Items 3.03, 5.03, 9.01
SC TO-I filing
10-Q filing
Show 5 more recent filings
Offerings
Registration 333-291359
Filing attachments
tm2625953d2_ex99-1.htm · 8-K · 2026-09-24
Exhibit 99.1 FOR IMMEDIATE RELEASE Clywedog Therapeutics Announces Final Results from a Phase 1b Study of Balomenib in Type 2 Diabetes Patients, Showing Glycemic Improvement Sustained for Three Months After a Three-Week Course of Treatment o Placebo-adjusted mean HbA1c reduction of 0.77% at Week 12 (p<0.01) and 0.70% at Week 16 (p<0.05) — three months after the last dose — following only three weeks of balomenib treatment o Statistically signific…
Read attachment ↗tm2530015d15_ex99-1.htm · S-4/A · 2026-04-13
EX-99.1 5 tm2530015d15_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Consent of Oppenheimer & Co. Inc. Oppenheimer & Co. Inc. (“Oppenheimer”) hereby consents to the inclusion of our opinion letter, dated September 29, 2025, to the Board of Directors (in its capacity as such) of Barinthus Biotherapeutic PLC (“Barinthus Bio”) included as Annex G, and to the references thereto under the captions “Summary - Opinion of Oppenheimer as Financial Advisor of Barinthus Bio,” “The Transactions - Background o…
Read attachment ↗